Identification of a 24-kDa cytokine that is required for development of cytolytic T lymphocytes by Cernetti, Cristina et al.
Rockefeller University 
Digital Commons @ RU 
Publications Steinman Laboratory Archive 
1988 
Identification of a 24-kDa cytokine that is required for 
development of cytolytic T lymphocytes 
Cristina Cernetti 
Ralph M. Steinman 
Angela Granelli-Piperno 
Follow this and additional works at: https://digitalcommons.rockefeller.edu/steinman-publications 
Proc. Nadl. Acad. Sci. USA
Vol. 85, pp. 1605-1609, March 1988
Immunology
Identification of a 24-kDa cytokine that is required for development
of cytolytic T lymphocytes
(dendritic cells/interleukin 2/cytotoic differentiation factor/lymphokines)
CRISTINA CERNETrI, RALPH M. STEINMAN, AND ANGELA GRANELLI-PIPERNO
The Rockefeller University and Irvington House Institute, New York, NY 10021
Communicated by Zanvil A. Cohn, October 23, 1987
ABSTRACT It is known that the production of cytolytic T
lymphocytes requires growth factors such as interleukins 2
and 4 (IL-2 and IL-4). Elsewhere we have described bioassays
that detect a cytokine that operates in concert with growth
factor to generate cytolytic T lymphocytes. The factor that is
termed cytolytic T-lymphocyte differentiation factor (CDF),
together with IL-2 and lectin, mediates the formation ofCD8+
killer cells in 2 days from thymocyte or peripheral lymphoid
precursors. CDF is not mimicked by natural or recombinant
sources of interferons, colony-stimulating factors, and IL-1 to
IL-4. Here we use these bioassays to isolate and further
characterize a single 24-kDa CDF protein from the condi-
tioned medium of stimulated human blood mononuclear cells.
CDF is first enriched by three successive chromatographic
procedures that utilize anion exchange, hydroxyapatite, and
phenyl-Superose. A single 24-kDa band with CDF activity is
then isolated on 12% NaDodSO4/PAGE and dearly distin-
guished from the 17-kDa band of 1L-2. The apparent molec-
ular mass is similar under reducing and nonreducing condi-
tions. After elution from NaDodSO4/PAGE the cytokine is
maximally active at 0.25 nM in the CDF assay and has no
growth factor activity for T lymphoblasts. To generate cyto-
lytic CD8', CD4- cells from spleen and lymph node T
lymphocytes, IL-2 and small numbers of accessory dendritic
cells must be applied together with CDF.
The development of cell-mediated immunity requires poly-
peptides termed cytokines or lymphokines. These proteins
operate at subnanomolar levels to bring about the growth
and/or differentiation of the different cell types that partic-
ipate in the immune response. The production of killer or
cytolytic T lymphocytes (CTL), the subject of this paper,
requires a 17-kDa growth factor termed interleukin 2 (IL-2)
in vivo and in vitro (1-5). The availability of a rapid and
reliable bioassay allowed IL-2 to be purified by biochemical
approaches (6-10). Recent evidence indicates that a second
growth factor, IL-4, can mimic IL-2 in the production of
CTL (11).
There are several models (reviewed in ref. 12) describing
the need for supplementary factors in conditioned medium,
in addition to IL-2, for the production of CTL. These
factors, often termed CTL differentiation factors (CDF),
have yet to be purified. We recently have identified two
rapid bioassays in which CDF and IL-2 are both required for
the development ofCTL (12). One assay utilizes thymocytes
from select strains of mice, and the other utilizes peripheral
T cells cultured in the presence of hydrocortisone. In each
assay CD8+ killer cells arise in 2 days in the presence of
lectins, IL-2, and CDF. A large panel of previously defined
cytokines has been tested and found to lack CDF activity.
Here we use these bioassays to identify a 24-kDa protein
with CDF activity from the conditioned medium of stimu-
lated human blood cells.
MATERIALS AND METHODS
Preparation of Human Leukocyte-Conditioned Medium (H-
CM). Human blood mononuclear cells were isolated from
leukocyte buffy coats by using Ficoll/Hypaque columns and
suspended at 107 cells per ml in RPMI 1640 medium (GIBCO)
supplemented with gentamicin (20 Ag/ml, GIBCO), phorbol
12-myristate 13-acetate (20 ng/ml, Sigma), and phytohemag-
glutinin (5%, GIBCO). Twenty-five milliliters of the suspen-
sion was applied to 150-mm plastic Petri dishes (Falcon) to
which the cells adhered because of the absence of serum
proteins. After 2 hr, the monolayers were washed twice. The
cells were recultured 38 hr in serum-free and mitogen-free
RPMI 1640 medium with gentamicin. The conditioned me-
dium was collected, concentrated 10-fold with a YM10 Ami-
con ultrafiltration membrane, and stored at - 20°(.
Bioassays. CDF was assayed in two systems (12). One was
used to monitor the purification of CDF. Thymocytes (5 x
10) from Swiss mice were cultured in RPMI 1640 medium
supplemented with test cytokines, gentamicin, 5% fetal calf
serum (Sterile Systems, Logan, UT), and 1 ug of Con A per
ml (Miles) in flat-bottomed microtest trays (Costar, no. 3596,
Cambridge, MA). After 42 hr, 104 51Cr-labeled P815 cells
were added as targets in the presence of 10 ug of phytohe-
magglutinin per ml (Difco). After 4 hr, the supernatants were
harvested to measure specific isotope release. Under these
culture conditions, the observed cell-mediated lympholysis
was due to Thy-1 +, CD8 +, CD4- cells (12). We also tested
enriched fractions of CDF in a second bioassay that used
peripheral T cells from lymph node or spleen. The culture
conditions were identical to the thymocyte assay except that
the lymphocytes were nylon wool-nonadherent, a cells,
and the medium was supplemented with 0.1 mM hydrocor-
tisone acetate (Sigma). Hydrocortisone acetate ablated the
formation of killer cells in response to lectin and IL-2 alone
(see Results). As accessory cells, we tested bulk plastic-
adherent, spleen cells as well as the adherent, dendritic cell
subpopulation enriched as described (13). IL-2 activity was
tested in a 1-day bioassay in which one measures the growth
of lectin-primed mouse spleen T blasts (8, 12).
Purified Cytokines. We were generously provided with
several purified cytokines that were not available at the time
of our initial studies of CDF (12). These cytokines, none of
which proved to have CDF activity (see Results), were
murine recombinant granulocyte/macrophage colony-
stimulating factor (rGM-CSF) (S. Gillis, Immunex, Seattle,
WA; 4 x 107 units/mg), human recombinant granulocyte
Abbreviations: CTL, cytolytic T lymphocyte(s); TGF, transforming
growth factor; IL, interleukin; r, recombinant; CDF, CTL differen-
tiation factor(s); IFN, interferon; CSF, colony-stimulating factor;
G-CSF, granulocyte CSF; GM-CSF, granulocyte/macrophage CSF;
H-CM, human leukocyte-conditioned medium.
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FIG. 1. Bioassay for a CDF in H-CM. Thymocytes were
cultured for 2 days in the presence of Con A and H-CM (e), H-CM
depleted of IL-2 on anti-IL-2 columns (o), 30 units of human rIL-2
per ml (o; Biogen, Cambridge, MA), or IL-2 with IL-2-depleted
H-CM as a source of CDF (A). Lysis of P815 targets in the presence
of additional lectin was measured (12). The immunoglobulin fraction
of a rabbit anti-human IL-2 antiserum, R135 (kindly provided by R.
Robb, DuPont, Glenolden, PA), was coupled to CnBr-activated
Sepharose (Pharmacia). Depletion of IL-2 was performed and mon-
itored as described (12).
CSF (rG-CSF) (L. Souza, Amgen Biologicals, Thousand
Oaks, CA; 8 x 107 units/mg), purified mouse IL-3 (Gen-
zyme, Norwalk, CT; 5000 colony-forming units/ml), and
purified porcine transforming growth factor, type 13 (TGF-/3)
(R & D Systems, Minneapolis, MN; 106 half-maximal units/-
mg).
Biochemical Methods. All chromatographic procedures
were performed at room temperature on a Waters HPLC
system and are described in detail in the figure legends.
NaDodSO4/PAGE was done with a Laemmli system with a
12% separating gel (14). Marker proteins were low molecular
mass standards of Pharmacia (Uppsala, Sweden). Gels were
silver stained as described (15). Protein determinations were
based on UV absorption at 280 nm or were estimated with







Table 1. Effect of different cytokines in the CDF bioassay
% specific lysis
Without With rIL-2
Factor added Concentration rIL-2 (30 units/ml)
None 0.3 1.7
H-CM 30%6 (vol/vol) 58.9 NT
15% (vol/vol) 44.2 NT
Murine rGM-CSF 10 ng/ml 0 3.1
3 ng/mI 0.1 1.7
Human rG-CSF 400 units/ml 1.0 2.0
160 units/ml 0.1 1.3
Murine purified IL-3 50 units/ml 0.8 3.8
20 units/ml 0.5 3.0
Porcine rTGF-j3 1 ng/ml 0.1 0.7
0.3 ng/ml 1.1 2.1
Thymocytes (3 x 105) were cultured 2 days with 1 Ag of Con A
per ml and the factors indicated. Half of the cultures in addition
received human rIL-2. At 44 hr, 5 x 103 51Cr-labeled P815 cells and
1 Ag of PHA per ml were added to each well. Release of radiolabel
was determined 4 hr later. NT, not tested.
Anti-IL-2 AffInity Chromatography. IL-2 was removed
from H-CM by passage over a rabbit anti-human IL-2
column as described (12).
RESULTS
Bioassay for a Distinct CDF. The bioassay that was used to
identify CDF is summarized in Fig. 1. When mouse thy-
mocytes from select strains of mice were cultured in H-CM
and lectin, cytotoxic activity was generated within 2 days.
CTL did not develop if the H-CM was depleted of IL-2 by
anti-IL-2 affinity chromatography (Fig. 1; ref. 12). Recom-
binant IL-2 (rIL-2) by itself did not induce CTL but did
reconstitute H-CM that had been depleted of IL-2 (Fig. 1).
CDF is defined as that factor or factors in H-CM that
mediated the development of CTL in concert with IL-2.
CDF is also present in the CM of stimulated mouse leuko-
cytes but not in the CM of macrophages stimulated with
lipopolysaccharide or EL-4 thymoma cells stimulated with
phorbol 12-myristate 13-acetate (12).
A large panel of purified mouse and human cytokines was
shown to lack CDF activity in prior work. The inactive
molecules included IL-1, IL-3, and IL-4; lymphotoxin and
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FIG. 2. Elution ofCDF and IL-2 from HPLC Mono Q anion-exchange columns. A Mono Q HR 10/10 column (Pharmacia) was equilibrated
with 10 mM Tris-HCl (pH 7.4). Concentrated H-CM in the same buffer was applied and eluted with a linear gradient of NaCl to 1 M at 4 ml/min.
Fractions (2 ml) were collected, and aliquots were assayed for CDF (e, lytic activity in the thymocyte assay with exogenous human rIL-2 at
10 units/ml), IL-2 (o, proliferation of T lymphoblasts; 3H-TdR, [3H]thymidine), and protein content (-, A280)





































































































FIG. 4. Elution of CDF and IL-2 from HPLC phenyl-Superose
columns. A Pharmacia HPLC phenyl-Superose HR 5/5 column was
equilibrated with 50 mM phosphate (pH 7.0) in 1 M ammonium
sulfate. The active fractions from the hydroxyapatite column (Fig. 3)
were made 1 M with ammonium sulfate, applied, and eluted with
decreasing ammonium sulfate to 0 M (50 mM phosphate). The
elution rate was 0.5 ml/min. Fractions (0.3 ml) were collected.
Following dialysis into phosphate-buffered saline, the fractions were
tested for CDF (W) and IL-2 (o; 'H-TdR, ['H]thymidine) activities.
The shaded area in A shows the fractions that were pooled for
subsequent purification.
FIG. 3. Elution of CDF and IL-2 from HPLC
hydroxyapatite columns. A Rainin HPLC HCA
column was equilibrated with 5 mM phosphate
buffer at pH 7.0. The active fractions from the
Mono Q columns (Fig. 2) in the same buffer were
applied and eluted with a linear gradient of so-
dium phosphate from 5 mM to 0.2 M at 1 ml/min
(A). Fractions (0.3 ml) were collected and tested
for protein content (A) and CDF (e) and IL-2 (0;
'H-TdR, [PHithymidine) activity (B). The shaded
area in A shows the fractions that were pooled for
further purification.
cachectin/tumor necrosis factor; macrophage CSF; and in-
terferons a, ,B, and y (IFN-a, IFN-,B, and IFN-y) (12). Here
we tested preparations of mouse rGM-CSF, human rG-CSF,
rTGF-,3, and purified mouse IL-3. All were inactive in
mediating CTL development alone or in combination with
IL-2 (Table 1). These results indicate that a different factor is
required for the development of at least some CTL from
noncytolytic precursors.
Purification of CDF. Since a short reliable assay was
available, we attempted to purify CDF to better define its
biologic role and biochemical characteristics. We performed
four cycles of purification. In each we started with 1600 ml of
H-CM that was obtained by stimulating 16 x 109 human
blood mononuclear cells with phorbol 12-myristate 13-
acetate and PHA in serum-free medium. The H-CM was
concentrated 10-fold and dialyzed against the appropriate
buffer to provide 150-190 mg of starting protein. The puri-
fication protocol that we developed involved three chro-
matographic steps followed by a final separation on
NaDodSO4/PAGE.
HPLC anion-exchange chromatography. The concen-
trated H-CM was loaded on a HPLC Mono Q column and
eluted with a linear NaCl gradient. CDF activity eluted
between 0.06 and 0.16 M NaCl and substantially overlapped
with IL-2 activity (Fig. 2). The active fractions were pooled
and contained 11-24 mg of protein.
HPLC hydroxyapatite chromatography. This step pro-
vided a substantial concentration of the CDF-containing
material that was obtained from the Mono Q column. Fol-
lowing elution with a linear sodium phosphate gradient, CDF
was recovered at about 50 mM. Again, CDF and IL-2
activities overlapped (Fig. 3). The positive fractions were
pooled and contained 3.3-3.7 mg of protein.
HPLC hydrophobic interaction chromatography. Material
from hydroxyapatite columns was applied to phenyl-
Superose and eluted with a decreasing gradient of 1-0 M
(NH4)2S04. CDF eluted at about 0.5 M. Phenyl-Superose








































FIG. 5. Isolation of CDF and
IL-2 on NaDodSO4/PAGE. Pos-
itive fractions from the HPLC
phenyl-Superose columns were
dialyzed against NaDodSO4, lyo-
philized, and reconstituted in
sample buffer to give a final con-
centration of 1% NaDodSO4.
Following electrophoresis in a
12% polyacrylamide gel, 1-mm
slices were prepared and eluted
into 1:10 phosphate-buffered sa-
line. Samples were assayed for
CDF (e) and IL-2 (o; 3H-TdR,
[3H]thymidine). The molecular
masses of the positive fractions
(shown in kDa) were estimated
by comparison with standards.
resolved quite nicely the peaks of CDF and IL-2 activity
(Fig. 4). The pooled fractions had 0.3-0.4 mg of protein with
CDF activity.
NaDodSO4/PAGE. The active fractions from phenyl-
Superose were separated on 12% acrylamide gels. Lanes
were then cut in 1-mm slices, eluted, and assayed for CDF
and IL-2 activities. CDF was recovered as a single peak,
with an apparent molecular mass of 24 kDa. IL-2 was
completely distinct and migrated at 17 kDa (Fig. 5). Sixteen
to 25 ug of purified CDF was obtained on each of the four
cycles of purification that we performed. Fractions of each
step of the purification were separated on NaDodSO4/
PAGE and analyzed by silver staining (Fig. 6). Each step,
particularly phenyl-Superose, led to a progressive reduction
of protein bands. A single band at 24 kDa was evident after
the final step under reducing (Fig. 6A) and nonreducing (Fig.
6B) conditions.
Biological Effects of Purified CDF. Dose-response studies
with purified CDF in the thymocyte bioassay indicated that
maximal cytotoxic responses were obtained at 0.25 nM (Fig.
7). The activity of CDF could be higher given the facts that
A
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67-












FIG. 6. NaDodSO4/PAGE of active fractions from the purifica-
tion protocol. (A) Silver staining of samples run under nonreducing
conditions. Lane 1, molecular mass standards; lane 2, concentrated
H-CM; lane 3, CDF fractions from the Mono Q column; lane 4, CDF
fractions from the hydroxyapatite column; lane 5, CDF fractions
from phenyl-Superose; lane 6, the final CDF fraction from the
preparative gel. (B) Silver staining of samples run under reducing
conditions. Lane 1, molecular mass standards; lane 2, the CDF
fraction from the preparative gel.
some denaturation may occur during the final separation in
detergent and some contaminants may comigrate with CDF.
The purified CDF was also tested on peripheral T cells
(12). Bulk or CD8 + (L3T4 -), spleen, or lymph node T cells
were obtained by passage over nylon wool and depletion of
residual Ia' accessory cells. For peripheral T cells, it was
essential to add 0.1 mM hydrocortisone acetate to block the
development of lytic cells that was observed with IL-2 alone
(12). In the presence of hydrocortisone acetate, substantial
levels of lytic activity developed in the combined presence of
lectin, CDF, IL-2, and accessory cells (Fig. 8). The lytic
activity was ablated by treatment with anti-CD8 but not
anti-CD4 monoclonal antibody and complement (data not
shown), indicating that the lytic cells developing in response
to pure CDF were primarily CTL rather than natural killer
cells. The purified CDF had no mitogenic activity for periph-
eral T cells (not shown).
DISCUSSION
CTL represent an important form of adaptive immunity.
CTL are able to eliminate cells bearing foreign antigens in an
antigen-specific and major histocompatibility complex-
restricted fashion. The known targets of CTL include trans-
plants bearing major and minor transplantation antigens,
cells infected with virus, and tumors. By using different
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FIG. 7. Activity of purified CDF in the thymocyte bioassay.
Purified CDF at the indicated doses were added to the thymocyte
bioassay, with additional human rIL-2 at 20 units/ml, and CTL were
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FIG. 8. Activity of purified CDF in the peripheral T-cell
bioassay. Nylon wool-nonadherent spleen lymph node cells were
depleted of residual accessory cells by panning with a combination
of anti-Fc receptor and anti-Ia monoclonal antibody. Accessory cell
depletion was evident in the fact that CTL did not develop in the
presence of lectin and there was no cell proliferation (not shown).
Enriched T cells (2.5 x 10) were cultured in microtest wells with
lectin in the absence (A) or presence (B) of 0.1 mM hydrocortisone
acetate and in the absence or presence of accessory cells. The
accessory cells were bulk adherent populations added at a submax-
imal dose of 1 adherent to 3 T cells or enriched dendritic cells (DC)
added at a submaximal dose of 1:300. Results are shown for CDF (60
ng/ml), CDF with human rIL-2 (10 units/ml), rlL-2 alone, or H-CM
[30% (vol/vol)].
required for the development of CTL in a polyclonal model.
Activity is associated with a single protein band in Na-
DodSO4 with an apparent molecular mass of 24 kDa. The
CDF has been enriched about 1000-fold from serum-free
conditioned medium. The protocol described here involves
anion exchange, adsorption and elution from hydroxyapa-
tite, and hydrophobic interaction chromatography. Taking
advantage of the stability of CDF in the presence of deter-
gent, we used an electrophoretic step in polyacrylamide gels
as a major purification step (Fig. 6). Additional procedures
will be required to determine if the single 24-kDa band is
contaminated with other proteins. If we assume that the
protein is pure and that denaturation did not occur, then
CDF is fully active at 0.25 nM (Fig. 7).
CDF has no detectable growth factor activity since we
observe neither blastogenesis nor DNA synthesis with rest-
ing T cells or primed T lymphoblasts (Fig. 5 and data not
shown). However, CDF mediates CTL development only in
concert with IL-2 and accessory dendritic cells (Fig. 8).
Given the role of dendritic cells in triggering lymphokine
release and responsiveness (16, 17), these accessory cells
may allow the T cell to become responsive to CDF or may
induce the release of yet another required factor.
One defined cytokine that has been reported to have CDF
activity has been IFN-y (18, 19). However, we have repeat-
edly found no enhancing effect of mouse or human rIFN-y in
our bioassays over a dose range of 1-100 units/ml (12).
Recently, a T-cell-derived stimulatory factor for B lympho-
cytes termed IL-S has been shown to have CDF activity in a
different bioassay (20). Human and mouse IL-5 have a
molecular mass of 45 kDa (20, 21). A large panel of known
cytokines (12) (Table 1) lacks CDF activity in the bioassays
we have employed. Therefore we suspect that CDF is a
previously unreported entity.
Further studies (as with specific neutralizing antibodies)
should clarify if CDF is an essential cytokine for antigen-
specific CTL differentiation. Many precedents exist for the
requirement of distinct differentiation and growth factors in
T-cell-mediated immunity. The production of microbicidal
and tumoricidal macrophages requires cytokines such as
IFN-y that act as "activation" rather than growth factors
(22). Production of specific B-cell isotypes in T-dependent
antibody responses also requires cytokines such as IL-4 and
IFN-y (23-25), but these cytokines do not act as growth
factors on the primed B lymphoblast (26).
Preliminary experiments indicate that the CD4+ subset of
blood T cells is much more active than the CD8 + subset for
the production of CDF. Additional evidence that CDF is a
T-cell product or lymphokine comes from prior work with
the immunosuppressive drug cyclosporin A. A major effect
of this drug is to block lymphokine production at the
transcriptional level. We have noted that the mRNA for
CDF could not be detected in oocyte translation systems
following application of cyclosporin A (27). Glucocorticoids
also suppress lymphokine production (28). We find that it is
essential to add steroid to our peripheral T-cell cultures to
observe the requirement for exogenous CDF in CTL devel-
opment. It is possible that the steroid acts to block the
production of endogenous CDF from helper or other cells.
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